![](images/graphics/blank.gif)
Nonsmall cell lung cancer
-
Chemoradiotherapy is a critical treatment for patients with locally advanced and unresectable nonsmall cell lung cancer (NSCLC), and it is essential to identify high-risk patients as early as possible owing to the high incidence of radiation pneumonitis (RP). This study aimed to investigate the value of computed tomography (CT)-based radiomics combined with genomics in analyzing the risk of grade≥2 RP in unresectable stage III NSCLC.
10p
vishanshan
27-06-2024
1
1
Download
-
EGFR inhibitor and immunotherapy have been approved for adjuvant treatment in resectable nonsmall cell lung cancer (NSCLC). Limited reports of molecular and clinical characteristics as prognostic factors in NSCLC have been published.
14p
vikoch
27-06-2024
3
1
Download
-
This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam. Methods This retrospective study was conducted across nine hospitals in Vietnam. Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received afatinib as first-line therapy between April 2018 and June 2022 were included, and patient medical records were reviewed.
10p
vikoch
27-06-2024
1
1
Download
-
Neoadjuvant immune checkpoint inhibitors(ICIs) combined with chemotherapy can improve nonsmall cell lung cancer(NSCLC) patients’ pathological responses and show promising improvements in survival.
11p
vikoch
27-06-2024
1
1
Download
-
This retrospective cohort study examined the impact of tetracyclines (TCs) and proton pump inhibitors (PPIs) alone or in combination on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKIs) in patients with non-small cell lung cancer (NSCLC).
12p
vischultz
20-10-2023
1
1
Download
-
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study
Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a reallife setting.
11p
vischultz
20-10-2023
2
1
Download
-
Numerous studies have demonstrated that the high-order features (HOFs) of blood test data can be used to predict the prognosis of patients with different types of cancer. Although the majority of blood HOFs can be divided into inflammatory or nutritional markers, there are still numerous that have not been classified correctly, with the same feature being named differently
15p
visharma
20-10-2023
3
3
Download
-
Radical resection plus lymph node dissection is a common treatment for patients with T1-3N0M0 nonsmall cell lung cancer (NSCLC). Few models predicted the survival outcomes of these patients. This study aimed to developed a nomogram for predicting their overall survival (OS).
9p
vioracle
29-09-2023
6
3
Download
-
Wilms’ tumour gene 1 (WT1) is clearly recognized as a tumour promoter in diversiform of human malignancies. Nevertheless, knowledge of its expression, functions and potential molecular mechanisms in non-small cell lung cancer (NSCLC) remains elusive.
15p
vioracle
29-09-2023
4
2
Download
-
The development of drug resistance and high mortality rates are the major problems observed in nonsmall cell lung cancer (NSCLC). Biomarkers indicating and predicting disease development towards these unfavorable directions are therefore on high demand.
13p
vioracle
29-09-2023
4
2
Download
-
Lung cancer is the second most common cancer worldwide. Nonsmall cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitutes 3-5%. Crizotinib was approved for the first-line therapy of advanced ALK-positive NSCLC patients.
3p
viintuit
26-09-2023
1
0
Download
-
Long-read sequencing of full-length cDNAs enables the detection of structures of aberrant splicing isoforms in cancer cells. These isoforms are occasionally translated, presented by HLA molecules, and recognized as neoantigens.
30p
viarchimedes
26-01-2022
13
0
Download
-
Vinorelbine monotherapy has been shown to be effective in recurrent or metastatic nonsmall cell lung cancer. This study aimed at evaluating the treatment results of vinorelbine monotherapy in lung cancer patients relapsed after curative treatment.
7p
inception36
30-11-2021
13
1
Download
-
Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all sites of the disease might be beneficial for patients with oligometastatic NSCLC.
6p
vimahuateng
26-11-2021
7
0
Download
-
The predictive role of blood-based tumor mutation burden (bTMB) for selecting advanced nonsmall cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs) is still under debate.
17p
vimahuateng
26-11-2021
6
1
Download
-
Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive nonsmall cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy.
11p
vimahuateng
26-11-2021
14
1
Download
-
PIKfyve is an evolutionarily conserved lipid and protein kinase enzyme that has pleiotropic cellular functions. The aim of the present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) inhibitor, YM201636, on nonsmall cell lung cancer (NSCLC) cells growth, tumorigenicity, and claudin (CLDN) expressions. Three NSCLC cell lines (Calu-1, H1299 and HCC827) were used to compare the effects of YM201636. Cytotoxic effects of YM201636 were analysed using XTT assay.
9p
thiencuuchu
27-11-2021
10
1
Download
-
Angiogenesis assessment is important for personalized therapeutic intervention in patients with nonsmall-cell lung cancer (NSCLC). This study investigated whether radiologic parameters obtained by dynamic contrast-enhanced (DCE)-integrated magnetic resonance-positron emission tomography (MR-PET) could be used to quantitatively assess tumor angiogenesis in NSCLC.
13p
vianrose2711
27-04-2021
10
1
Download
-
Although repeat pulmonary resection (RPR) for multiple lung cancer has been performed for nonsmall cell lung cancer and metastatic lung tumor, with the prognostic beneft detailed in several reports, the risk of RPR has not been well analyzed.
6p
vianthony2711
16-04-2021
5
1
Download
-
Screening mutations in epidermal growth factor receptor (EGFR) to analyze non-small-cell lung cancer (NSCLC) profile is the criterion to choose the best therapeutic strategy. New Oncology guidelines recommend EGFR mutation analysis before prescribing tyrosine kinase inhibitors (TKIs) treatment.
8p
vimontana2711
05-04-2021
12
1
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)